Immunovant Inc Dossier - Source-backed chat

Immunovant Inc

IMVTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.88

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $33.65Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $7B

Enterprise Value $6.2B

Shares Outstanding 217.1M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Immunovant is a high-potential, clinical-stage immunology company focused on developing next-generation FcRn inhibitors. Following the strategic discontinuation of its legacy asset batoclimab due to missed Phase 3 endpoints in thyroid eye disease, the company has successfully pivoted and concentrated its resources on its lead asset, IMVT-1402. IMVT-1402 has demonstrated best-in-class potential, highlighted by compelling Phase 2 data in difficult-to-treat rheumatoid arthritis (D2T RA) with strong response rates and a clean safety profile. Backed by a robust cash position of $902.1 million, Immunovant possesses a solid financial runway extending through the potential commercial launch of IMVT-1402 in Graves' disease, mitigating near-term dilution risks and positioning the company for significant clinical catalysts in late 2026 and 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets16 analysts · as of 18 Aug 2026

Low · most bearish analyst$24.00

Mean target$47.88

High · most bullish analyst$66.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$24.00

IMVT-1402 encounters unexpected safety concerns or fails to replicate its strong Phase 2 efficacy in larger registrational trials. Regulatory delays or intense competition from established players (such as argenx) limit the commercial potential of the asset, forcing the company to seek additional capital under unfavorable terms and depressing the valuation.

Base CaseCentral scenario

$47.88

Matches the consensus mean

IMVT-1402 successfully advances through registrational trials in Graves' disease and myasthenia gravis with topline data in 2027 confirming its competitive profile. The cash runway remains sufficient to support operations through these key readouts without requiring highly dilutive capital raises. The stock trades in line with consensus expectations reflecting solid progress of the pipeline.

Bull CaseUpside scenario

$66.00

IMVT-1402 achieves best-in-class status across multiple high-value autoimmune indications, including Graves' disease, myasthenia gravis, and rheumatoid arthritis. Clinical trials deliver outstanding efficacy with no significant safety signals (such as LDL cholesterol elevation), leading to rapid regulatory approvals and peak global sales exceeding $6 billion. Strong market adoption and favorable pricing dynamics drive the stock toward the high-end analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

IMVT-1402 has demonstrated best-in-class potential with strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis and a highly favorable safety profile.
A robust cash position of $902.1 million as of March 31, 2026, provides a long operational runway through key clinical milestones and potential commercial launch.
Strategic focus has been sharpened by discontinuing the legacy batoclimab program, redirecting resources and capital to the higher-potential IMVT-1402 asset.

Key Investment Risks

The company is clinical-stage and pre-revenue, making its valuation highly dependent on binary clinical trial outcomes.
High development costs and rising R&D expenses ($456.7 million in FY2026) could accelerate cash burn if trials face delays.
Intense competition in the FcRn inhibitor space from well-capitalized biopharmaceutical companies.

Thesis Invalidation Triggers

Failure of IMVT-1402 to meet primary endpoints in upcoming registrational trials for Graves' disease or myasthenia gravis.
Emergence of adverse safety signals, such as significant lipid or albumin changes, during longer-term dosing of IMVT-1402.
Inability to maintain the projected cash runway, leading to premature and highly dilutive equity offerings.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.